

### IN THE CLAIMS

Please cancel claims 34, 38, 40-42, 49 and 50 without prejudice to Applicants' right to pursue the subject matter of these claims. Please amend claims 31, 36, 37, 39, 44, 45, 47 and 48 as follows:

1. – 30. (CANCELED)

31. (CURRENTLY AMENDED) A synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and which comprises the a nucleotide sequence shown in SEQ ID NO: 10 selected from the group consisting of TGACGTCA and SEQ ID NOS: 1-4, 6-12, 14-15, 18-101, 103, 105, 107 and 109, wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

32. – 35. (CANCELED)

36. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 ~~34~~, wherein the oligonucleotide is 45 up to 70 nucleotides in length.

37. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 ~~34~~, wherein the oligonucleotide is 45 up to 50 nucleotides in length, ~~and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, 18-101, 103, 105, 107 and 109.~~

38. (CANCELED)

39. (WITHDRAWN AND AMENDED) The synthetic oligonucleotide of claim 31 ~~34~~, wherein the oligonucleotide is 30 nucleotides in length, ~~and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, 18-101, 103, 105, 107 and 109.~~

40. (CANCELED)

41. (CANCELED)
42. (CANCELED)
43. (WITHDRAWN) A pharmaceutically acceptable salt of a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.
44. (WITHDRAWN AND AMENDED) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 31 ~~34~~.
45. (WITHDRAWN AND AMENDED) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 32 ~~41~~.
46. (PREVIOUSLY PRESENTED) A composition comprising a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide, and a pharmaceutically acceptable carrier.
47. (WITHDRAWN AND AMENDED) A composition comprising the synthetic oligonucleotide of claim 31 ~~34~~ and a pharmaceutically acceptable carrier.
48. (WITHDRAWN AND AMENDED) A composition comprising the synthetic oligonucleotide of claim 39 ~~44~~ and a pharmaceutically acceptable carrier.
49. (CANCELED)
50. (CANCELED)